In March 2025, Novo Nordisk purchased the rights to develop, manufacture, and market the drug UBT251 outside of China, Hong Kong, Taiwan, and Macau. (Archive photo). Photo: Jade Gao/Ritzau Scanpix
New Novo drug cuts weight and blood sugar in China
Novo Nordisk has presented results from a Phase 2 study of UBT251, a triple agonist drug developed with United Biotechnology. In the trial involving Chinese participants with type 2 diabetes, the drug achieved an average blood sugar reduction of 2.16% and weight loss of 9.8% over 24 weeks. These...
Get full access to Danish News in English
Gain exclusive access to daily news updates in English pertaining to Denmark with a Ritzau News subscription.
Already a subscriber?